Insiders · IKT

David Canner

Director at Inhibikase Therapeutics, Inc. (IKT) since October 2024

David Canner has filed 5 insider reports with the SEC since October 2024, as director at Inhibikase Therapeutics, Inc. (IKT). The latest filing, on June 30, 2026, reports grant or award at Inhibikase Therapeutics, Inc. (IKT).

Filings
5
Companies
1
Bought on market
None
Sold on market
None

Companies where David Canner is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Inhibikase Therapeutics, Inc. logo
IKT
Inhibikase Therapeutics, Inc.
Directorsince October 2024$1.32Jun 30, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare David Canner with

Other insiders at the same companies

Questions about David Canner

What is David Canner's role at Inhibikase Therapeutics, Inc.?
David Canner reports to the SEC as director at Inhibikase Therapeutics, Inc. (IKT), according to the latest filing on June 30, 2026.
Has David Canner bought or sold stock recently?
No open-market purchases or sales by David Canner are on file. The filings report grant or award.
How do I get alerts when David Canner files?
Follow David Canner on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by David Canner (SEC CIK 0002041173). Totals count each trade once, skipping amendments whose original is on file, from Oct 23, 2024 on. View on SEC EDGAR · Get this as JSON